Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 10, Issue 4, 2015, Pages 586-594

  Romanus, Dorothy ^a   Cardarella, Stephanie ^b   Cutler, David ^c   Landrum, Mary Beth ^b   Lindeman, Neal I ^d   Gazelle, G Scott ^e  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cost effectiveness; Lung cancer; Multiplexed test; Non small cell; Targeted therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PEMETREXED; DNA; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; UNITED STATES; UNSPECIFIED SIDE EFFECT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; FEMALE; GENE REARRANGEMENT; GENETIC SCREENING; GENETICS; LUNG NEOPLASMS; MALE; METABOLISM; MUTATION; PROCEDURES; RETROSPECTIVE STUDY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FEMALE; GENE REARRANGEMENT; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES;

EID: 84938290439     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000474     Document Type: Article

References (46)

1. American Cancer Society Key statistics about lung cancer. Available at: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics. Accessed June 4, 2013
2. Owonikoko TK, Ragin CC, Belani CP, Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007 25 5570 5577
3. Barlesi F, Blons H, Beau-Faller M, Biomarkers France: Preliminary results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients 2013 Chicago, Illinois; Presented at 2013 ASCO Annual Meeting. Available at: http://meetinglibrary.asco.org/content/114562-132. Accessed September 15, 2013
4. Lindeman NI, Cagle PT, Beasley MB, Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013 8 823 859
5. Lynch JA, Khoury MJ, Borzecki A, Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research. Genet Med 2013 15 630 638
6. Djalalov S, Beca J, Hoch JS, Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol 2014 32 1012 1019
7. Moran T, Sequist LV, Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. J Clin Oncol 2012 30 3330 3336
8. Cappuzzo F, Ciuleanu T, Stelmakh L, SATURN Investigators Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010 11 521 529
9. Atherly AJ, Camidge DR, The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer 2012 106 1100 1106
10. Handorf EA, McElligott S, Vachani A, Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J Oncol Pract 2012 8 267 274
11. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL, The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-Tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 2009 12 20 27
12. Arrieta O, Anaya P, Lopez RJ, Polanco AC, Cost-effectiveness analysis of EGFR mutation testing in patients with advanced non small-cell lung cancer (ANSCLC) treated with gefitinib or carboplatin-paclitaxel. Value Health 2010 13 A37 38
13. Chen W, Ellis P, Levin L, Krahn M, Cost-effectiveness of epidermal growth factor receptor gene mutation testing in the selection of first-line therapy for patients with advanced non-small cell lung cancer in Ontario. Value Health 2011 14 A82
14. Jacob J, Henriksson M, Brattstrbm D, Cost-effectiveness of gefitinib versus doublet chemotherapy in first-line treatment of non-small cell lung cancer (NSCLC) in Sweden. Value Health 2010 13 A270
15. Lopes GD, Segal J, Tan D, Do Y, Mok T, Finkelstein E, Cost-effectiveness of epidermal growth-factor receptor mutation testing and first-line treatment with gefitinib for advanced non-small-cell lung cancer. EJC Suppl 2011 9 2
16. Shiroiwa T, Miyoshi Y, Tsutani K, Cost-effectiveness analysis of EGFR testing and gefitinib for nonsmall-cell lung cancer (NSCLC) in Japan. Value Health 2012 15 A67
17. Borget I, Cadranel J, Pignon JP, ERMETIC Collaborative Group Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. Eur Respir J 2012 39 172 179
18. Gold MR, Siegal J, Russell LB, Weinstein MC, Cost-Effectiveness in Health and Medicine 1996 New York Oxford University Press
19. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J, Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008 6 84
20. Westwood ME, Joore M, Whiting P, van Asselt T, Ramaekers B, Armstrong N, Misso K, Severens J, Kleijnen J, Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer: a systematic review and cost-effectiveness analysis. Health Technol Assess 2014 18 1 166
21. Scagliotti GV, Parikh P, von Pawel J, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008 26 3543 3551
22. Paz-Ares L, de Marinis F, Dediu M, Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012 13 247 255
23. Rosell R, Carcereny E, Gervais R, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012 13 239 246
24. Brugger W, Triller N, Blasinska-Morawiec M, Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011 29 4113 4120
25. Shaw AT, Kim DW, Nakagawa K, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013 368 2385 2394
26. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, National Cancer Institute of Canada Clinical Trials Group Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 353 123 132
27. Jackman DM, Yeap BY, Lindeman NI, Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007 25 760 766
28. Paik JH, Choe G, Kim H, Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011 6 466 472
29. Clinical Laboratory Fee Schedule. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Gapfill-Pricing-Inquiries.html. Accessed May 12, 2013
30. Physician Fee Schedule. Available at: http://www.cms.gov/apps/physician-fee-schedule/search/search-results.aspx?Y=1&T=0&HT=0&CT=3&H1=88381&M=5. Accessed May 15, 2013
31. BDIPharma HCPCS codes & medicare payment. Available at: http://www.bdipharma.com/services-hcpcs-codes-medicare-payment.aspx. Accessed June 2, 2013
32. Price Rx Pro. Available at: https://pricerx.medispan.com. Accessed May 15, 2013
33. Veterans Affairs. MS-Diagnosis-Related Group (MS-DRG) weights (2008-2013). Available at: http://www.herc.research.va.gov/resources/faq-f03.asp. Accessed May 19, 2013
34. Yabroff KR, Lamont EB, Mariotto A, Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008 100 630 641
35. Bureau of Labor Statistics sual weekly earnings of wage and salary workers. Available at: http://www.bls.gov/news.release/wkyeng.toc.htm. Accessed May 17, 2013
36. US General Services Administration Privately owned vehicle (POV) mileage reimbursement rates. Available at: http://www.gsa.gov/. Accessed May 21, 2013
37. US Government GPO Chain-Type price indexes for gross domestic product, 1964-2012. Available at: http://www.gpo.gov/fdsys/granule/ERP-2013/ERP-2013-Table7/content-detail.html. Accessed June 2, 2013
38. Hunink M, Glasziou P, Siegel J, Decision-Making in Health and Medicine: Integrating Evidence and Values 2001 New York, NY Cambridge University Press
39. Roszkowski K, Pluzanska A, Krzakowski M, A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000 27 145 157
40. Worldbank GDP per capita (current US$). Available at: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed April 10, 2014
41. Ubel PA, Hirth RA, Chernew ME, Fendrick AM, What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003 163 1637 1641
42. Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, Hanna N, Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients. Cancer 2012 118 3173 3181
43. Experts in CML The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013 121 4439 4442
44. Hall S, The cost of living. Available at: http://nymag.com/news/features/cancer-drugs-2013-10/. Accessed July 3, 2014
45. Bach P SL, Wittes R, Cancer care, cost matters. Available at: http://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-To-An-11000-A-month-cancer-drug.html?-r=0. Accessed July 3, 2014
46. Mok T, Yang JJ, Lam KC, Treating patients with EGFR-sensitizing mutations: first line or second line-is there a difference? J Clin Oncol 2013 31 1081 1088